Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna operating margin
Operating margin is operating income as a percentage of revenue.
Moderna's operating margin for the twelve months ending Jun 30, 2026 was -149.0%. For fiscal 2025 it was -158.1%, against -121.9% the year before. The highest annual figure on record is 72.0% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -158.1% | −36.2 |
| FY2024 | Dec 31, 2024 | -121.9% | −60.0 |
| FY2023 | Dec 31, 2023 | -61.9% | −110.8 |
| FY2022 | Dec 31, 2022 | 48.9% | −23.1 |
| FY2021 | Dec 31, 2021 | 72.0% | +167.0 |
| FY2020 | Dec 31, 2020 | -95.0% | +815.0 |
| FY2019 | Dec 31, 2019 | -910.0% | −604.0 |
| FY2018 | Dec 31, 2018 | -306.0% | −175.1 |
| FY2017 | Dec 31, 2017 | -130.9% | +75.6 |
| FY2016 | Dec 31, 2016 | -206.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -562.1% | +76.7 |
| Q1 FY2026 | Mar 31, 2026 | -356.8% | +615.4 |
| Q4 FY2025 | Dec 31, 2025 | -126.4% | +2.6 |
| Q3 FY2025 | Sep 30, 2025 | -25.6% | −21.8 |
| Q2 FY2025 | Jun 30, 2025 | -638.7% | −73.2 |
| Q1 FY2025 | Mar 31, 2025 | -972.2% | −214.1 |
| Q4 FY2024 | Dec 31, 2024 | -129.0% | −129.2 |
| Q3 FY2024 | Sep 30, 2024 | -3.8% | +106.1 |
| Q2 FY2024 | Jun 30, 2024 | -565.6% | −22.8 |
| Q1 FY2024 | Mar 31, 2024 | -758.1% | −738.4 |
| Q4 FY2023 | Dec 31, 2023 | 0.2% | −30.9 |
| Q3 FY2023 | Sep 30, 2023 | -109.9% | −144.5 |
| Q2 FY2023 | Jun 30, 2023 | -542.7% | −594.3 |
| Q1 FY2023 | Mar 31, 2023 | -19.7% | −89.3 |
| Q4 FY2022 | Dec 31, 2022 | 31.1% | −43.9 |
| Q3 FY2022 | Sep 30, 2022 | 34.7% | −36.9 |
| Q2 FY2022 | Jun 30, 2022 | 51.5% | −18.8 |
| Q1 FY2022 | Mar 31, 2022 | 69.7% | +4.3 |
| Q4 FY2021 | Dec 31, 2021 | 75.0% | +123.2 |
| Q3 FY2021 | Sep 30, 2021 | 71.6% | +221.3 |
| Q2 FY2021 | Jun 30, 2021 | 70.3% | +252.4 |
| Q1 FY2021 | Mar 31, 2021 | 65.4% | +1702.9 |
| Q4 FY2020 | Dec 31, 2020 | -48.2% | +880.7 |
| Q3 FY2020 | Sep 30, 2020 | -149.7% | +617.4 |
| Q2 FY2020 | Jun 30, 2020 | -182.1% | +916.4 |
| Q1 FY2020 | Mar 31, 2020 | -1637.5% | −753.6 |
| Q4 FY2019 | Dec 31, 2019 | -928.9% | −496.9 |
| Q3 FY2019 | Sep 30, 2019 | -767.1% | −561.6 |
| Q2 FY2019 | Jun 30, 2019 | -1098.4% | −762.2 |
| Q1 FY2019 | Mar 31, 2019 | -883.9% | −617.3 |
| Q4 FY2018 | Dec 31, 2018 | -432.0% | −386.5 |
| Q3 FY2018 | Sep 30, 2018 | -205.5% | −45.7 |
| Q2 FY2018 | Jun 30, 2018 | -336.3% | −107.2 |
| Q1 FY2018 | Mar 31, 2018 | -266.5% | −50.7 |
| Q4 FY2017 | Dec 31, 2017 | -45.5% | – |
| Q3 FY2017 | Sep 30, 2017 | -159.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -229.1% | – |
| Q1 FY2017 | Mar 31, 2017 | -215.9% | – |
See a number that looks wrong?